Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NurExone Biologic Inc. NRXBF


Primary Symbol: V.NRX

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.


TSXV:NRX - Post by User

NurExone Biologic Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3214)
•••
Post by Betteryear2on Jun 22, 2023 3:19pm
203 Views
Post# 35509803

Regeneration & Reinnervation of Spinal Cord in Rats Treated

Regeneration & Reinnervation of Spinal Cord in Rats Treated TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive imaging results from an internal preclinical study of its investigational drug ExoPTEN. The image analysis and measurements confirmed successful nerve regeneration following traumatic transection of the spinal cord in rats. These imaging results align with previous results showing a remarkable recovery of motor function in 75% of paralyzed rats suffering from spinal cord injuries and treated with the new therapy.

Regeneration and Reinnervation of Spinal Cord in Rats (globenewswire.com)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities